Atossa Therapeutics Raises $4.5M with Warrants Offering Up to $12M More
ATOS•Atossa Therapeutics completed a registered direct offering of 1,363,638 common shares and accompanying warrants, generating $4.5 million in gross proceeds. Series A and B warrants covering up to 1,363,638 shares could yield an additional $12 million if fully exercised under six‐month and two‐year vesting schedules.
1. Offering Structure and Proceeds
Atossa Therapeutics entered into a registered direct offering of 1,363,638 common shares and Series A and B warrants, securing approximately $4.5 million in gross proceeds before fees. The offering closed or is expected to close on June 12, 2026, subject to customary conditions.
2. Warrant Terms and Potential Upside
The Series A warrants become exercisable six months after issuance and expire 5.5 years later, while Series B warrants vest immediately and expire in two years. If fully exercised on a cash basis, these warrants could provide up to $12 million in additional capital.
3. Use of Proceeds and Strategic Impact
Net proceeds are earmarked for clinical development of lead product candidates, general working capital, and corporate purposes. This financing extends the company’s runway for its oncology pipeline, including the (Z)-endoxifen program across multiple clinical settings.
